TAIWAN LIPOSOME/S (NASDAQ:TLC) Receives “Buy” Rating from HC Wainwright

Share on StockTwits

TAIWAN LIPOSOME/S (NASDAQ:TLC)‘s stock had its “buy” rating restated by equities research analysts at HC Wainwright in a note issued to investors on Thursday, AnalystRatings.com reports. They currently have a $11.00 price objective on the stock. HC Wainwright’s target price points to a potential upside of 103.79% from the company’s current price.

A number of other research analysts have also issued reports on TLC. Cantor Fitzgerald dropped their price objective on shares of TAIWAN LIPOSOME/S from $11.00 to $10.00 and set an “overweight” rating for the company in a report on Wednesday. ValuEngine upgraded shares of TAIWAN LIPOSOME/S from a “hold” rating to a “buy” rating in a report on Tuesday, December 31st. Finally, Zacks Investment Research lowered shares of TAIWAN LIPOSOME/S from a “buy” rating to a “hold” rating in a report on Wednesday, January 29th. One investment analyst has rated the stock with a hold rating and four have given a buy rating to the company’s stock. The stock has a consensus rating of “Buy” and an average price target of $9.00.

Shares of NASDAQ TLC opened at $5.40 on Thursday. The company has a 50 day simple moving average of $5.38 and a 200 day simple moving average of $5.23. The firm has a market cap of $200.24 million, a PE ratio of -9.64 and a beta of 0.78. TAIWAN LIPOSOME/S has a 1 year low of $4.61 and a 1 year high of $8.54. The company has a debt-to-equity ratio of 0.14, a current ratio of 2.01 and a quick ratio of 2.01.

A hedge fund recently raised its stake in TAIWAN LIPOSOME/S stock. Millennium Management LLC raised its position in shares of TAIWAN LIPOSOME/S (NASDAQ:TLC) by 564.6% in the third quarter, according to its most recent filing with the SEC. The firm owned 92,915 shares of the company’s stock after purchasing an additional 112,915 shares during the quarter. Millennium Management LLC owned approximately 0.29% of TAIWAN LIPOSOME/S worth $474,000 at the end of the most recent quarter. 2.11% of the stock is owned by institutional investors.

About TAIWAN LIPOSOME/S

Taiwan Liposome Company, Ltd., a clinical-stage specialty pharmaceutical company, engages in the development and commercialization of nanomedicines that combine its proprietary lipid-assembled drug delivery platform with approved active pharmaceutical ingredients (APIs). Its BioSeizer lipid formulation technology enables pharmacokinetic (PK) control and local sustained release of APIs at the site of disease or injury; and NanoX targeted delivery technology enables prolonged PK profiles and enhanced distribution of liposome-encapsulated APIs at the desired site.

Recommended Story: Balanced Fund

Receive News & Ratings for TAIWAN LIPOSOME/S Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for TAIWAN LIPOSOME/S and related companies with MarketBeat.com's FREE daily email newsletter.

 


Latest News

Yu Darvish Receives Cortisone Shot for Elbow Impingement
Yu Darvish Receives Cortisone Shot for Elbow Impingement
Red Sox and Brandon Phillips Agree to Minor League Deal
Red Sox and Brandon Phillips Agree to Minor League Deal
Chris Sale Proves He is 2018 AL Cy Young Candidate
Chris Sale Proves He is 2018 AL Cy Young Candidate
Strong Results by Clint Frazier Could Keep Him with Yankees
Strong Results by Clint Frazier Could Keep Him with Yankees
Giants Closer Breaks Hand Punching Door Following Poor Outing
Giants Closer Breaks Hand Punching Door Following Poor Outing
Evan Longoria Out Six to Eight Weeks With Broken Hand
Evan Longoria Out Six to Eight Weeks With Broken Hand


 
© 2006-2020 BBNS.